Sermorelin
Also known as GRF (1-29)NH2, Geref
The 29-amino-acid active fragment of growth hormone-releasing hormone, formerly approved in the US for growth hormone deficiency in children.
Approved drug substance
Size
2 options- Catalog no.
- SMO5
- Specification
- 5mg*10vials
- Per kit
- 10 vials
For laboratory research use only. Not for human or animal consumption. Buyers must be 21 or older.
Overview
Sermorelin is the amidated 1-29 fragment of human GHRH, the shortest sequence with full biological activity. It was marketed in the US as Geref for diagnosing and treating growth hormone deficiency in children, and its manufacturer discontinued it in 2008 for commercial reasons rather than safety concerns. Because it stimulates the pituitary rather than replacing GH, the resulting secretion stays subject to normal feedback by somatostatin and IGF-1, which made it a subject of research in ageing and GH physiology.
Class: GHRH analogue (GRF 1-29)
Mechanism of action
How the compound acts, as described in the literature.
Binds the GHRH receptor on anterior pituitary somatotrophs, activating adenylyl cyclase and cAMP signaling.
Stimulates both synthesis and release of endogenous growth hormone in a pulsatile pattern.
GH released this way remains under negative feedback from somatostatin and IGF-1.
Its short plasma half-life, from cleavage by dipeptidyl peptidase-4, limits the duration of each stimulus.
Published research
Selected studies, each linked to its PubMed record. Summaries describe what the studies reported.
1996
Multicenter clinical trial
PMID 8772599Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.
Thorner M, et al. · J Clin Endocrinol Metab
In GH-deficient children, a year of daily GHRH therapy increased mean height velocity compared with baseline.
1997
Human pilot study
PMID 9005976Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.
Vittone J, et al. · Metabolism
In 11 men aged 64–76, six weeks of nightly GHRH raised nocturnal GH release but did not change IGF-I, body composition or most strength measures; no significant adverse effects were seen.
Evidence & safety
What the research does not show, and the adverse events and regulatory status it reports.
US marketing (Geref) ended in 2008 for commercial reasons. Outside pediatric GH deficiency, evidence comes from small, short studies; in older men, single nightly dosing did not raise IGF-I. Long-term outcomes in adults have not been established.
Specifications
All sizes, exactly as catalogued.
| Catalog no. | Product | Specification | Vials per kit |
|---|---|---|---|
| SMO5 | Sermorelin | 5mg*10vials | 10 |
| SMO10 | Sermorelin | 10mg*10vials | 10 |
For laboratory research use only. Not for human or animal consumption. Not intended to diagnose, treat, cure or prevent any disease. Research summaries are provided for educational purposes and do not describe this product’s use.